Related Experiment Video
Updated: Feb 2, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Current understanding and perioperative management of pediatric pulmonary hypertension
Gregory J Latham1, Delphine Yung2
1Department of Anesthesiology and Pain Medicine, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington.
Insights
Pediatric pulmonary hypertension presents diverse causes and risks. Anesthesiologists must understand its physiology and anesthetic implications for improved patient outcomes.
Area of Science:
- Pediatric Cardiology
- Anesthesiology
- Pulmonology
Background:
- Pediatric pulmonary hypertension (PPH) encompasses diverse etiologies from neonates to young adults.
- Pediatric pulmonary arterial hypertension (PAH) is progressive and lethal, while neonatal forms, though often transient, carry significant risks.
- Pulmonary hypertension secondary to left heart disease is an emerging concern in pediatric populations.
Purpose of the Study:
- To review the current understanding of pediatric pulmonary hypertension (PPH).
- To highlight the heightened risks associated with anesthesia and sedation in children with PPH.
- To emphasize the critical role of anesthesiologists in managing PPH patients perioperatively.
Main Methods:
- Comprehensive literature review of pediatric pulmonary hypertension.
- Analysis of pathophysiological mechanisms across different PPH subtypes.
- Evaluation of anesthetic considerations and risk stratification strategies.
Main Results:
- PPH is a complex condition with varied causes, impacting patient safety during anesthesia.
- Anesthetic management requires a thorough understanding of PPH pathophysiology.
- Perioperative care, from preoperative assessment to postoperative management, is crucial for mitigating risks.
Conclusions:
- Anesthesiologists require specialized knowledge of PPH to ensure patient safety.
- Effective perioperative strategies are essential for reducing morbidity and mortality in pediatric patients with pulmonary hypertension.
- This review provides a foundation for understanding PPH physiology and anesthetic implications.
Abstract:
Pediatric pulmonary hypertension is a complex disease with multiple, diverse etiologies affecting the premature neonate to the young adult. Pediatric pulmonary arterial hypertension, whether idiopathic or associated with congenital heart disease, is the most commonly discussed form of pediatric pulmonary hypertension, as it is progressive and lethal. However, neonatal forms of pulmonary hypertension are vastly more frequent, and while most cases are transient, the risk of morbidity and mortality in this group deserves recognition. Pulmonary hypertension due to left heart disease is another subset increasingly recognized as an important cause of pediatric pulmonary hypertension. One aspect of pediatric pulmonary hypertension is very clear: anesthetizing the child with pulmonary hypertension is associated with a significantly heightened risk of morbidity and mortality. It is therefore imperative that anesthesiologists who care for children with pulmonary hypertension have a firm understanding of the pathophysiology of the various forms of pediatric pulmonary hypertension, the impact of anesthesia and sedation in the setting of pulmonary hypertension, and anesthesiologists' role as perioperative experts from preoperative planning to postoperative disposition. This review summarizes the current understanding of pediatric pulmonary hypertension physiology, preoperative risk stratification, anesthetic risk, and intraoperative considerations relevant to the underlying pathophysiology of various forms of pediatric pulmonary hypertension.
More Related Videos
Related Concept Videos
Hypertension V: Nursing Management
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Embolism III: Nursing Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

